LGD-4033 is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis. Recent studies investigated the effects of LGD-4033 on muscle tissue in ovariectomized rats. A daily dose of LGD-4033 was administered and calculated according to the bodyweight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD-4033 treatment. This difference remained until the end of the study, irrespective of LGD-4033 treatments. Additionally, the LGD-4033 treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.
|Molar Mass||338.253 g·mol−1|